Barriers to Uptake of PrEP and Potential Solutions

Release date: November 8, 2019

Expiration date: November 8, 2020

Estimated time to complete activity: 1 hour and 45 minutes

This activity is jointly provided by the Postgraduate Institute for Medicine and the American Academy of HIV Medicine.

This activity is supported by an independent educational grant from Quest Diagnostics.

aahivm logo

Target Audience
This activity has been designed to meet the educational needs of physicians, physician assistants, pharmacists and nurse practitioners actively prescribing PrEP medications.

Educational Objectives
After completing this activity, the participant should be better able to:
  • Identify ways to better address the challenges of PrEP uptake
  • Discuss clinical trial opportunities
  • Determine the knowledge level of healthcare providers in prescribing PrEP
  • Improve communications with patients on PrEP adherence

Gina M. Simoncini, MD MPH FACP AAHIVS
Associate Professor of Clinical Medicine
Lewis Katz School of Medicine at Temple University

Joint Accreditation Statement
In support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine and American Academy of HIV Medicine. Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician Continuing Education
The Postgraduate Institute for Medicine designates this enduring material for a maximum of 1.75 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Continuing Pharmacy Education
Postgraduate Institute for Medicine designates this continuing education activity for 1.75 contact hour(s) (0.175 CEUs) of the Accreditation Council for Pharmacy Education (Universal Activity Number – JA4008162-9999-19-976-H02-P)

Type of Activity: Application

Disclosure of Conflicts of Interest

Gina M. Simoncini , MD, MPH, FACP, AAHIVS
Consulting fees from Quest Diagnostics
Research funding from Gilead Sciences, Inc.

Planners and Managers
The PIM planners and managers have nothing to disclose. The AAHIVM planners and managers have nothing to disclose.

Postgraduate Institute for Medicine (PIM) requires instructors, planners, managers and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to PIM policy. PIM is committed to providing its learners with high quality CME activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.

Method of Participation and Request for Credit:
There are no fees for participating and receiving CME/CE credit for this activity. During the period November 8, 2019 through November 8, 2020 participants must read the learning objectives and faculty disclosures and study the educational activity.

If you wish to receive acknowledgment for completing this activity, please complete the post-test and evaluation on www.cmeuniversity.com. On the navigation menu, click on “Find Post-test/Evaluation by Course” and search by course ID 14828. Upon registering and successfully completing the post-test with a score of 75% or better and the activity evaluation, your certificate will be made available immediately.

For Pharmacists: Upon successfully completing the post-test with a score of 75% or better and the activity evaluation form, transcript information will be sent to the NABP CPE Monitor Service within 4 weeks.

Media: Internet

CME University requires a modern web browser (Internet Explorer 7+, Mozilla Firefox, Apple Safari, Google Chrome). Certain educational activities may require additional software to view multimedia, presentation, or printable versions of their content. These activities will be marked as such and will provide links to the required software. That software may be: Adobe Flash, Apple QuickTime, Adobe Acrobat, Microsoft PowerPoint, Windows Media Player, and Real Networks Real One Player.

Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners.  Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

In this activity the faculty do discuss the use of investigational antiretroviral agents and treatment regimens that are not approved by treatment guidelines.

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.